Recently, Noh et al. discovered that the introduction of paclitaxel into human cancer cells led to the reduction of H3K9me3 marks via SETDB1 transcriptional downregulation, as well as induction of p53 leading to cell death in a G2/M arrest manner. The gene discussed is SETDB1; the disease is cancer.